TY - JOUR AU - Llovet, J. M. AU - Ricci, S. AU - Mazzaferro, V. AU - Hilgard, P. AU - Gane, E. AU - Blanc, J. F. PY - 2008 DA - 2008// TI - Sorafenib in advanced hepatocellular carcinoma JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708857 DO - 10.1056/NEJMoa0708857 ID - Llovet2008 ER - TY - JOUR AU - Mittal, S. AU - El-Serag, H. B. PY - 2013 DA - 2013// TI - Epidemiology of hepatocellular carcinoma: consider the population JO - J Clin Gastroenterol VL - 47 UR - https://doi.org/10.1097/MCG.0b013e3182872f29 DO - 10.1097/MCG.0b013e3182872f29 ID - Mittal2013 ER - TY - JOUR AU - Coriat, R. AU - Nicco, C. AU - Chereau, C. AU - Mir, O. AU - Alexandre, J. AU - Ropert, S. PY - 2012 DA - 2012// TI - Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-12-0093 DO - 10.1158/1535-7163.MCT-12-0093 ID - Coriat2012 ER - TY - JOUR AU - Tan, W. F. AU - Qiu, Z. Q. AU - Yu, Y. AU - Ran, R. Z. AU - Yi, B. AU - Lau, W. Y. PY - 2010 DA - 2010// TI - Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation JO - Acta Pharmacol Sin VL - 31 UR - https://doi.org/10.1038/aps.2010.124 DO - 10.1038/aps.2010.124 ID - Tan2010 ER - TY - JOUR AU - Li, Y. AU - Gao, Z. H. AU - Qu, X. J. PY - 2015 DA - 2015// TI - The adverse effects of sorafenib in patients with advanced cancers JO - Basic Clin Pharmacol Toxicol VL - 116 UR - https://doi.org/10.1111/bcpt.12365 DO - 10.1111/bcpt.12365 ID - Li2015 ER - TY - JOUR AU - Zhu, A. X. AU - Finn, R. S. AU - Edeline, J. AU - Cattan, S. AU - Ogasawara, S. AU - Palmer, D. PY - 2018 DA - 2018// TI - Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30351-6 DO - 10.1016/S1470-2045(18)30351-6 ID - Zhu2018 ER - TY - JOUR AU - Camby, I. AU - Mercier, M. AU - Lefranc, F. AU - Kiss, R. PY - 2006 DA - 2006// TI - Galectin-1: a small protein with major functions JO - Glycobiology. VL - 16 UR - https://doi.org/10.1093/glycob/cwl025 DO - 10.1093/glycob/cwl025 ID - Camby2006 ER - TY - JOUR AU - Zheng, L. AU - Xu, C. AU - Guan, Z. AU - Su, X. AU - Xu, Z. AU - Cao, J. PY - 2016 DA - 2016// TI - Galectin-1 mediates TGF-beta-induced transformation from normal fibroblasts into carcinoma-associated fibroblasts and promotes tumor progression in gastric cancer JO - Am J Transl Res VL - 8 ID - Zheng2016 ER - TY - JOUR AU - Wang, F. AU - Lv, P. AU - Gu, Y. AU - Li, L. AU - Ge, X. AU - Guo, G. PY - 2017 DA - 2017// TI - Galectin-1 knockdown improves drug sensitivity of breast cancer by reducing P-glycoprotein expression through inhibiting the Raf-1/AP-1 signaling pathway JO - Oncotarget. VL - 8 ID - Wang2017 ER - TY - JOUR AU - Zhou, X. AU - Li, D. AU - Wang, X. AU - Zhang, B. AU - Zhu, H. AU - Zhao, J. PY - 2015 DA - 2015// TI - Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.3076 DO - 10.18632/oncotarget.3076 ID - Zhou2015 ER - TY - JOUR AU - Zhang, P. F. AU - Li, K. S. AU - Shen, Y. H. AU - Gao, P. T. AU - Dong, Z. R. AU - Cai, J. B. PY - 2016 DA - 2016// TI - Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling JO - Cell Death Dis VL - 7 UR - https://doi.org/10.1038/cddis.2015.324 DO - 10.1038/cddis.2015.324 ID - Zhang2016 ER - TY - JOUR AU - Delord, J. P. AU - Awada, A. AU - Raymond, E. AU - Lokiec, E. AU - Herait, P. AU - Rezai, K. PY - 2013 DA - 2013// TI - A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors JO - Mol Cancer Ther VL - 12 ID - Delord2013 ER - TY - JOUR AU - Zhang, J. AU - Yang, Y. AU - Yang, T. AU - Liu, Y. AU - Li, A. AU - Fu, S. PY - 2010 DA - 2010// TI - microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumorigenicity JO - Br J Cancer VL - 103 UR - https://doi.org/10.1038/sj.bjc.6605895 DO - 10.1038/sj.bjc.6605895 ID - Zhang2010 ER - TY - JOUR AU - Luo, L. J. AU - Zhang, L. P. AU - Duan, C. Y. AU - Wang, B. AU - He, N. N. AU - Abulimiti, P. PY - 2017 DA - 2017// TI - The inhibition role of miR-22 in hepatocellular carcinoma cell migration and invasion via targeting CD147 JO - Cancer Cell Int VL - 17 UR - https://doi.org/10.1186/s12935-016-0380-8 DO - 10.1186/s12935-016-0380-8 ID - Luo2017 ER - TY - JOUR AU - Tey, S. K. AU - Tse, E. Y. T. AU - Mao, X. AU - Ko, F. C. F. AU - Wong, A. S. T. AU - Lo, R. C. PY - 2017 DA - 2017// TI - Nuclear met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-kappaB pathway JO - Cancer Lett VL - 411 UR - https://doi.org/10.1016/j.canlet.2017.09.047 DO - 10.1016/j.canlet.2017.09.047 ID - Tey2017 ER - TY - JOUR AU - Xu, D. AU - Takeshita, F. AU - Hino, Y. AU - Fukunaga, S. AU - Kudo, Y. AU - Tamaki, A. PY - 2011 DA - 2011// TI - miR-22 represses cancer progression by inducing cellular senescence JO - J Cell Biol VL - 193 UR - https://doi.org/10.1083/jcb.201010100 DO - 10.1083/jcb.201010100 ID - Xu2011 ER - TY - JOUR AU - Eales, K. L. AU - Hollinshead, K. E. AU - Tennant, D. A. PY - 2016 DA - 2016// TI - Hypoxia and metabolic adaptation of cancer cells JO - Oncogenesis. VL - 5 UR - https://doi.org/10.1038/oncsis.2015.50 DO - 10.1038/oncsis.2015.50 ID - Eales2016 ER - TY - JOUR AU - White, N. M. AU - Masui, O. AU - Newsted, D. AU - Scorilas, A. AU - Romaschin, A. D. AU - Bjarnason, G. A. PY - 2014 DA - 2014// TI - Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis JO - Br J Cancer VL - 110 UR - https://doi.org/10.1038/bjc.2013.828 DO - 10.1038/bjc.2013.828 ID - White2014 ER - TY - JOUR AU - Le, Q. T. AU - Shi, G. AU - Cao, H. AU - Nelson, D. W. AU - Wang, Y. AU - Chen, E. Y. PY - 2005 DA - 2005// TI - Galectin-1: a link between tumor hypoxia and tumor immune privilege JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.02.0206 DO - 10.1200/JCO.2005.02.0206 ID - Le2005 ER - TY - JOUR AU - Chen, S. AU - Zhang, J. AU - Chen, J. AU - Wang, Y. AU - Zhou, S. AU - Huang, L. PY - 2019 DA - 2019// TI - RER1 enhances carcinogenesis and stemness of pancreatic cancer under hypoxic environment JO - J Exp Clin Cancer Res VL - 38 UR - https://doi.org/10.1186/s13046-018-0986-x DO - 10.1186/s13046-018-0986-x ID - Chen2019 ER - TY - JOUR AU - Jo, J. AU - Choi, S. AU - Oh, J. AU - Lee, S. G. AU - Choi, S. Y. AU - Kim, K. K. PY - 2019 DA - 2019// TI - Conventionally used reference genes are not outstanding for normalization of gene expression in human cancer research JO - BMC Bioinformatics VL - 20 UR - https://doi.org/10.1186/s12859-019-2809-2 DO - 10.1186/s12859-019-2809-2 ID - Jo2019 ER - TY - JOUR AU - Bruix, J. AU - Qin, S. AU - Merle, P. AU - Granito, A. AU - Huang, Y. H. AU - Bodoky, G. PY - 2017 DA - 2017// TI - Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet. VL - 389 UR - https://doi.org/10.1016/S0140-6736(16)32453-9 DO - 10.1016/S0140-6736(16)32453-9 ID - Bruix2017 ER - TY - CHAP AU - Raymond, E. r. i. c. AU - Astrorgue-Xerri, L. u. c. i. l. e. AU - Serova, M. a. r. i. a. AU - Riveiro, M. a. r. i. a. E. u. g. e. n. i. a. AU - Faivre, S. a. n. d. r. i. n. e. PY - 2012 DA - 2012// TI - Translational Rational for the Clinical Development of OTX-008: A Novel Drug That Inhibits Galectin-1 Expression in Human Cancer Models BT - ACS Symposium Series PB - American Chemical Society CY - Washington, DC ID - Raymond2012 ER - TY - JOUR AU - Colagrande, S. AU - Regini, F. AU - Taliani, G. G. AU - Nardi, C. AU - Inghilesi, A. L. PY - 2015 DA - 2015// TI - Advanced hepatocellular carcinoma and sorafenib: diagnosis, indications, clinical and radiological follow-up JO - World J Hepatol VL - 7 UR - https://doi.org/10.4254/wjh.v7.i8.1041 DO - 10.4254/wjh.v7.i8.1041 ID - Colagrande2015 ER - TY - JOUR AU - Wdowiak, K. a. m. i. l. AU - Francuz, T. o. m. a. s. z. AU - Gallego-Colon, E. n. r. i. q. u. e. AU - Ruiz-Agamez, N. a. t. a. l. i. a. AU - Kubeczko, M. a. r. c. i. n. AU - GrochoĊ‚a, I. g. a. AU - Wojnar, J. e. r. z. y. PY - 2018 DA - 2018// TI - Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives JO - International Journal of Molecular Sciences VL - 19 UR - https://doi.org/10.3390/ijms19010210 DO - 10.3390/ijms19010210 ID - Wdowiak2018 ER -